Related Experiment Video
Updated: Oct 5, 2025
04:34
Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
884
Facial Edema Associated with Dasatinib: Case Report with Successful Treatment
Timothy Nyckowski1, Austin Ambur1, Alisa Vinokurov2
1Department of Dermatology, KCU-GME Advanced Dermatology and Cosmetic Surgery.
Summary
Facial edema, a rare side effect of tyrosine kinase inhibitors (TKI) used for chronic myeloid leukemia (CML), can be effectively managed with a combination of topical metronidazole and tacrolimus, allowing continued TKI therapy.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKI) are crucial for chronic myeloid leukemia (CML) treatment.
- Common TKI side effects include cytopenias and gastrointestinal issues.
- Facial edema is a rare but burdensome TKI adverse effect requiring management options.
Observation:
- A 70-year-old female with CML developed a facial rash and edema after starting dasatinib.
- The patient had a history of diabetes, hypertension, and hypercholesterolemia.
Findings:
- A novel regimen of topical metronidazole 1% gel and topical tacrolimus 0.1% ointment was initiated.
- The patient experienced significant improvement in facial edema and rash.
- This topical regimen allowed for continued dasatinib treatment.
Implications:
- Topical metronidazole and tacrolimus offer an alternative to corticosteroids for TKI-induced facial edema.
- This combination may mitigate long-term side effects associated with prolonged corticosteroid use.
- Further research is warranted to evaluate the efficacy and safety of this regimen.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
519
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
519
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
275
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
275